Literature DB >> 33739994

Risk factors for symptomatic Avascular Necrosis (AVN) in a multi-ethnic Systemic Lupus Erythematosus (SLE) cohort.

Syahrul Sazliyana Shaharir1, Siew Huoy Chua2, Rozita Mohd3, Ruslinda Mustafar3, Malehah Mohd Noh4, Nor Shuhaila Shahril5, Mohd Shahrir Mohamed Said1, Sakthiswary Rajalingham1.   

Abstract

Avascular necrosis of bone (AVN) is increasingly being recognized as a complication of SLE and causes significant disability due to pain and mobility limitations. We studied the prevalence and factors associated with avascular necrosis (AVN) in a multiethnic SLE cohort. SLE patients who visited the outpatient clinic from October 2017 to April 2019 were considered eligible. Their medical records were reviewed to identify patients who developed symptomatic AVN, as confirmed by either magnetic resonance imaging or plain radiography. Subsequently, their SLE disease characteristics and treatment were compared with the characteristics of patients who did not have AVN. Multivariable logistic regression analyses were performed to determine the independent factors associated with AVN among the multiethnic SLE cohort. A total of 390 patients were recruited, and the majority of them were females (92.6%); the patients were predominantly of Malay ethnicity (59.5%), followed by Chinese (35.9%) and Indian (4.6%). The prevalence of symptomatic AVN was 14.1%, and the mean age of AVN diagnosis was 37.6 ± 14.4 years. Both univariate and multivariable logistic regression analyses revealed that a longer disease duration, high LDL-C (low density lipoprotein cholesterol), positive anti-cardiolipin (aCL) IgG and anti-dsDNA results, a history of an oral prednisolone dose of more than 30 mg daily for at least 4 weeks and osteoporotic fractures were significantly associated with AVN. On the other hand, hydroxychloroquin (HCQ), mycophenolate mofetil (MMF) and bisphosphonate use were associated with a lower risk of AVN. No associations with ethnicity were found. In conclusion, several modifiable risk factors were found to be associated with AVN, and these factors may be used to identify patients who are at high risk of developing such complications. The potential protective effects of HCQ, MMF and bisphosphonates warrant additional studies.

Entities:  

Year:  2021        PMID: 33739994      PMCID: PMC7978335          DOI: 10.1371/journal.pone.0248845

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  41 in total

1.  Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective.

Authors:  L Cozen; D J Wallace
Journal:  Am J Orthop (Belle Mead NJ)       Date:  1998-05

2.  Hospitalized avascular necrosis after renal transplantation in the United States.

Authors:  Kevin C Abbott; Robert J Oglesby; Lawrence Y Agodoa
Journal:  Kidney Int       Date:  2002-12       Impact factor: 10.612

3.  Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus.

Authors:  Sau Mei Tse; Chi Chiu Mok
Journal:  Lupus       Date:  2016-11-12       Impact factor: 2.911

4.  Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?

Authors:  A Rascu; K Manger; H G Kraetsch; J R Kalden; B Manger
Journal:  Lupus       Date:  1996-08       Impact factor: 2.911

5.  Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus.

Authors:  S C M S Fialho; E Bonfá; L F Vitule; E D'Amico; V Caparbo; S Gualandro; R M R Pereira
Journal:  Lupus       Date:  2007       Impact factor: 2.911

Review 6.  Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.

Authors:  Toshiyuki Sakaeda; Tsutomu Nakamura; Katsuhiko Okumura
Journal:  Pharmacogenomics       Date:  2003-07       Impact factor: 2.533

7.  Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone.

Authors:  D T Felson; J J Anderson
Journal:  Lancet       Date:  1987-04-18       Impact factor: 79.321

8.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

9.  Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic.

Authors:  V Golder; K Connelly; M Staples; E Morand; A Hoi
Journal:  Lupus       Date:  2013-08-13       Impact factor: 2.911

10.  Damage in the Multiethnic Malaysian Systemic Lupus Erythematosus (SLE) Cohort: Comparison with Other Cohorts Worldwide.

Authors:  Syahrul Sazliyana Shaharir; Heselynn Hussein; Sakthiswary Rajalingham; Mohd Shahrir Mohamed Said; Abdul Halim Abdul Gafor; Rozita Mohd; Ruslinda Mustafar
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

View more
  4 in total

1.  Accumulation of LDL/ox-LDL in the necrotic region participates in osteonecrosis of the femoral head: a pathological and in vitro study.

Authors:  Xin-Yuan Wang; Tian-Le Ma; Kang-Ning Chen; Zhi-Ying Pang; Hao Wang; Jun-Ming Huang; Guo-Bin Qi; Chen-Zhong Wang; Zeng-Xin Jiang; Lin-Jing Gong; Zhe Wang; Chang Jiang; Zuo-Qin Yan
Journal:  Lipids Health Dis       Date:  2021-11-25       Impact factor: 3.876

Review 2.  Bone Involvement in Systemic Lupus Erythematosus.

Authors:  Valeria Rella; Cinzia Rotondo; Alberto Altomare; Francesco Paolo Cantatore; Addolorata Corrado
Journal:  Int J Mol Sci       Date:  2022-05-22       Impact factor: 6.208

3.  Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.

Authors:  Manuel Francisco Ugarte-Gil; Anselm Mak; Joanna Leong; Bhushan Dharmadhikari; Nien Yee Kow; Cristina Reátegui-Sokolova; Claudia Elera-Fitzcarrald; Cinthia Aranow; Laurent Arnaud; Anca D Askanase; Sang-Cheol Bae; Sasha Bernatsky; Ian N Bruce; Jill Buyon; Nathalie Costedoat-Chalumeau; Mary Ann Dooley; Paul R Fortin; Ellen M Ginzler; Dafna D Gladman; John Hanly; Murat Inanc; David Isenberg; Soren Jacobsen; Judith A James; Andreas Jönsen; Kenneth Kalunian; Diane L Kamen; Sung Sam Lim; Eric Morand; Marta Mosca; Christine Peschken; Bernardo A Pons-Estel; Anisur Rahman; Rosalind Ramsey-Goldman; John Reynolds; Juanita Romero-Diaz; Guillermo Ruiz-Irastorza; Jorge Sánchez-Guerrero; Elisabet Svenungsson; Murray Urowitz; Evelyne Vinet; Ronald F van Vollenhoven; Alexandre Voskuyl; Daniel J Wallace; Michelle A Petri; Susan Manzi; Ann Elaine Clarke; Mike Cheung; Vernon Farewell; Graciela S Alarcon
Journal:  Lupus Sci Med       Date:  2021-12

4.  Effect of physiotherapy rehabilitation on stage 4 avascular necrosis of femur following pyogenic arthritis: a case report.

Authors:  Akshaya Virendra Saklecha; Om Chandrakant Wadhokar; Deepali Swapnil Patil; Waqar Mohsin Naqvi
Journal:  Pan Afr Med J       Date:  2022-01-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.